TRPM4 in Cancer-A New Potential Drug Target.

Borgström, Anna; Peinelt, Christine; Stoklosa, Paulina (2021). TRPM4 in Cancer-A New Potential Drug Target. Biomolecules, 11(2) MDPI 10.3390/biom11020229

[img]
Preview
Text
biomolecules-11-00229.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (827kB) | Preview

Transient receptor potential melastatin 4 (TRPM4) is widely expressed in various organs and associated with cardiovascular and immune diseases. Lately, the interest in studies on TRPM4 in cancer has increased. Thus far, TRPM4 has been investigated in diffuse large B-cell lymphoma, prostate, colorectal, liver, breast, urinary bladder, cervical, and endometrial cancer. In several types of cancer TRPM4 is overexpressed and contributes to cancer hallmark functions such as increased proliferation and migration and cell cycle shift. Hence, TRPM4 is a potential prognostic cancer marker and a promising anticancer drug target candidate. Currently, the underlying mechanism by which TRPM4 contributes to cancer hallmark functions is under investigation. TRPM4 is a Ca2+-activated monovalent cation channel, and its ion conductivity can decrease intracellular Ca2+ signaling. Furthermore, TRPM4 can interact with different partner proteins. However, the lack of potent and specific TRPM4 inhibitors has delayed the investigations of TRPM4. In this review, we summarize the potential mechanisms of action and discuss new small molecule TRPM4 inhibitors, as well as the TRPM4 antibody, M4P. Additionally, we provide an overview of TRPM4 in human cancer and discuss TRPM4 as a diagnostic marker and anticancer drug target.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Faculty Institutions > NCCR TransCure
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Biochemistry and Molecular Medicine

UniBE Contributor:

Borgström, Anna; Peinelt, Christine and Stoklosa, Paulina Agnieszka

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health

ISSN:

2218-273X

Publisher:

MDPI

Language:

English

Submitter:

Barbara Järmann-Bangerter

Date Deposited:

27 Apr 2021 16:16

Last Modified:

27 Apr 2021 16:16

Publisher DOI:

10.3390/biom11020229

PubMed ID:

33562811

Uncontrolled Keywords:

calcium cancer drug target ion channel migration prognostic marker proliferation

BORIS DOI:

10.48350/154260

URI:

https://boris.unibe.ch/id/eprint/154260

Actions (login required)

Edit item Edit item
Provide Feedback